The use of metalloprotease inhibitors (45) or specific freezing protocols to protect NK cells (46) may reverse this loss of signal and increase the potential of NKp46 as a biomarker for ME/CFS. Here, NCR1 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.